Regular cranberry juice comsumption cuts UTIs

12 August 2007

Recent US research jointly conducted by scientists at Rutgers, the State University of New Jersey and the University of Michigan, suggests that regular consumption of cranberry juice cocktail could reduce the potential for development of urinary tract infections (UTIs), thus decreasing the need for antibiotics.

"With more and more awareness among health professionals and the public regarding antibiotic resistance, we are happy to report during our study when subjects consumed cranberry juice cocktail, their urine was capable of preventing antibiotic-resistant bacteria from adhering to cells from the urinary tract," said Amy Howell, lead investigator of the study.

In this investigation, scientists tested the effectiveness of cranberry juice cocktail in disabling a number of Escherichia coli bacteria, some of which are resistant to certain drugs. E. coli is responsible for a host of health problems including UTIs and has become increasingly drug resistant.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight